Health Canada Authorizes bioLytical's iStatis Syphilis Test, Boosting Rapid Response to Rising Infections in Canada
RICHMOND, British Columbia, July 22, 2025 (GLOBE NEWSWIRE) — bioLytical Laboratories Inc. ('bioLytical'), a global leader in rapid diagnostics, has received Health Canada authorization of its iStatis Syphilis Antibody Test. This milestone allows for immediate distribution across Canada, providing healthcare professionals with a powerful tool to screen for syphilis quickly and accurately in clinical and community settings.
'We are honoured to receive Health Canada authorization for our iStatis Syphilis Antibody Test,' said Robert Mackie, CEO of bioLytical. 'With syphilis rates rising in communities across Canada, it's more important than ever to equip healthcare professionals with fast, reliable tools. This authorization strengthens our ability to support Canada's public health efforts with timely, accurate testing.'
Fast, Accurate, and Designed for Real-World Use
The iStatis Syphilis Antibody Test is a lateral flow assay that detects antibodies to
Treponema pallidum
, the bacterium that causes syphilis. Designed for use by healthcare professionals, the test aids in diagnosis through a simple, fingerstick blood sample.
Key Benefits:
Strengthening Canada's Public Health Priorities
With rising rates across both urban and rural communities, particularly among populations with limited access to regular healthcare, expanding access to reliable syphilis testing is essential to achieving Canada's sexually transmitted and blood-borne infections (STBBI) strategy goals.
'The availability of a rapid syphilis antibody test capable of detecting the infection at different clinical stages is a significant advancement,' said Ana Subramanian, Vice President, Scientific Affairs at bioLytical. 'The iStatis platform supports earlier diagnosis and treatment, especially in high-burden regions where immediate screening is essential.'
Early detection remains one of the most effective tools in controlling the spread of syphilis. Because many infections can go undiagnosed due to mild or hidden symptoms, people may unknowingly transmit the infection to others. The introduction of the iStatis Syphilis Antibody Test provides Canadian healthcare providers with a powerful first-line testing option to identify infections earlier, initiate timely treatment, and help reduce the overall burden of syphilis nationwide.
Addressing the Rise of Congenital Syphilis
Canada is also experiencing a sharp increase in congenital syphilis, a preventable infection passed from parent to child during pregnancy. While reported cases have dropped from 2022, the Public Health Agency of Canada (PHAC) advises rates have increased drastically from 2018 by 220%.
If left undiagnosed, congenital syphilis can lead to serious outcomes, including miscarriage, stillbirth, low birth weight, and long-term complications. Early testing during pregnancy is vital to prevent transmission and protect maternal and infant health.
'Every case of congenital syphilis is preventable with early diagnosis and treatment,' said Ana Subramanian. 'Rapid tests like the iStatis Syphilis Antibody Test help providers act quickly and support safer outcomes for both parent and child. Expanding access to point-of-care testing is an important step toward closing prenatal care gaps and reducing congenital infections in Canada.'
Made in Canada, Available Coast-to-Coast
This milestone aligns with Canada's broader public health goals, emphasizing the importance of regular and widespread syphilis testing as a key strategy to reduce infection rates. With the iStatis Syphilis Antibody Test now available for professional use, bioLytical is committed to supporting healthcare providers nationwide in screening at-risk populations, connecting patients to care, and ultimately reducing the burden of syphilis in Canada.
bioLytical will manufacture the iStatis Syphilis Antibody Test at its Richmond, B.C. headquarters, in full compliance with MDSAP and ISO 13485:2016 standards. It is available nationwide through healthcare facilities, public health programs, and community-based organizations.
As a Canadian company with a global reach, bioLytical is committed to equipping healthcare providers with the tools they need to respond quickly and effectively to evolving public health challenges.
For more information, please visit
bioLytical's website
.
About bioLytical Laboratories Inc.:
bioLytical Laboratories Inc. is a privately owned Canadian company focused on researching, developing, and commercializing rapid medical diagnostics using its proprietary INSTI® technology platform and its lateral flow line, iStatis. By delivering accurate results in real-time, INSTI® and iStatis generate meaningful outcomes for medical professionals, patients, and public health organizations worldwide. We are key partners in tackling some of the world's most severe healthcare challenges. Please visit
www.biolytical.com
,
www.insti.com
, and
www.istatis.com
for more information.
Sources:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Lung Cancer Screening Market to Reach USD 7.44 Billion by 2032, Driven by LDCT Adoption and Growing High-Risk Population
Global Lung Cancer Screening Market Forecast (2025–2032) Shows 9.32% CAGR, U.S. Market to Hit USD 2.21 Billion by 2032 Amid Early Detection Demand and Technological Advancements. Austin, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Lung Cancer Screening Market Size & Growth Analysis: According to SNS Insider, The Lung Cancer Screening Market was estimated at USD 3.66 billion in 2024 and is expected to reach USD 7.44 billion by 2032, at a CAGR of 9.32% during the forecast period of 2025-2032. The global lung cancer screening market growth is driven by the increasing prevalence of lung cancer and growing adoption of screening, initiatives to increase awareness about lung cancer, and the introduction of new and advanced products. Favorable governmental policies, rising healthcare infrastructure, and technological advancements are other factors driving Free Sample Report of the Lung Cancer Screening Market: The U.S. lung cancer screening market was estimated at USD 1.12 billion in 2024 and is expected to reach USD 2.21 billion by 2032, at a CAGR of 8.89% during the forecast period of 2025-2032 The U.S. dominated the North American lung cancer screening market, driven by robust policy support and early uptake of low-dose computed tomography (LDCT) among the eligible high-risk population of 50 to 80-year-olds with a smoking history of 20+ pack-years under updated USPSTF guidelines. Segmentation & Regional Highlights By Modality, the LDCT Segment Dominates the Lung Cancer Screening Market in 2024 The low-dose computed tomography (LDCT) segment held the largest share of the lung cancer screening market in 2024 with a 61.2% market share owing to high accuracy, non-invasive nature, and support by such as the U.S. Preventive Services Task Force (USPSTF) and other major health societies. LDCT allows early lung cancer diagnosis in high-risk patients and dramatically improves survival. Incorporation of cancer screening and insurance coverage has facilitated adoption, particularly in the developed world. By Cancer Type, the Non-Small Cell Lung Cancer (NSCLC) Segment Dominates the Market and is Witnessing High Growth Over the Forecast Period Non-small cell lung cancer (NSCLC) segment held a major share of the lung cancer screening market in 2024 as a result of the high prevalence of NSCLC among the population, which accounts for nearly 85% of all lung cancer cases around the globe. NSCLC is slow compared to small cell lung cancer, making it possible for more cases to be found early and diagnosed during screening. The demand for NSCLC screening has also increased with the development of targeted therapies and biomarkers for NSCLC. The 60–69 Years Segment Dominated the Lung Cancer Screening Market by Age Group The 60–69 years age group dominated the Lung Cancer Screening Market in the year 2024, owing to the higher prevalence of lung cancer in this age group. Members of this group are usually longer-term smokers or have had more exposure to carcinogens, and are therefore at higher risk, justifying the need for regular screening. Many countries' medical guidelines give this age range priority for low-dose CT screening, which has driven an increase in use. Lung Cancer Screening Market in North America Led in 2024 with a 40.3% Market Share, APAC Poised to be the Fastest-Growing Regional Market. The lung cancer screening market in North America is driven by the well-developed healthcare system, early uptake of advanced screening technologies such as LDCT, and favorable reimbursement scenarios. Marked awareness of lung cancer, full-scale enforcement of national screening guidelines, and a strong position of key players provide additional prospects for regional supremacy. Screening programmes promoted by governmental institutions such as the U.S. Preventive Services Task Force (USPSTF) have increased the screening rates, especially in high-risk individuals, and the region has evolved into a global market leader. The Asia-Pacific lung cancer screening market is estimated to register the highest CAGR, on account of a rise in the incidence of lung cancer, increasing awareness, and the increasing healthcare expenditure in the region. China, India, Japan, and other countries are enhancing early cancer screening initiatives, expanding access to LDCT and biomarker testing. For a Personalized Briefing with Our Industry Analysts, Connect Now: Key Lung Cancer Screening Companies Profiled in the Report GE HealthCare Siemens Healthineers Philips Healthcare Canon Medical Systems Corporation Fujifilm Holdings Corporation Samsung Medison Co. Ltd. Carestream Health Shimadzu Corporation Vuno Inc. Zebra Medical Vision Aidoc Riverain Technologies Lunit Inc. Roche Diagnostics Illumina Inc. Guardant Health Exact Sciences Corporation Bio-Rad Laboratories CT Screening International and other players. Lung Cancer Screening Market Report Scope Report Attributes Details Market Size in 2024 US$ 3.66 billion Market Size by 2032 US$ 7.44 billion CAGR CAGR of 9.32% From 2025 to 2032 Base Year 2024 Forecast Period 2025-2032 Historical Data 2021-2023 Regional Analysis North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Key Growth Drivers Growing incidence of lung cancer worldwide Increased public awareness and government-led screening programs Advancements in imaging technologies (e.g., AI-enabled CT scans) Rising demand for non-invasive and early-stage cancer detection Supportive reimbursement policies in the U.S. and Europe Unique Selling Propositions (USPs) of the Report: Country-level eligibility for the screening landscape Assists your company in prioritizing markets that have high potential opportunity by comparing age, risk, and reimbursement criteria for screening across countries. Adoption curves comparison: LDCT vs. new technologies Facilitates strategic planning by identifying lung cancer screening early adopters vs. laggards for LDCT and next-gen technologies, and helps to launch market entry timing. Biomarker Inclusion in Lung Screening Helps companies make R&D and partnership decisions by monitoring how molecular diagnostics are supplementing or undercutting traditional screening. RoS (Return on Screening) Modelling Measures the cost per site of value of your screening programs to enable XYZ Company to create a persuasive business case for customers or reimbursement agencies, or health authorities. Buy the Full Lung Cancer Screening Market Report (Single-User License) Now: About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Navigating ADHICS Compliance: How MIT Consultants is Shaping Cybersecurity Standards in UAE Healthcare
Dubai, UAE,, Aug. 06, 2025 (GLOBE NEWSWIRE) -- As UAE healthcare and financial institutions race to meet stringent ADHICS regulations, MIT Consultants emerges as a trusted advisor, guiding enterprises toward robust compliance through tailored cybersecurity solutions. The cybersecurity landscape in the UAE has dramatically evolved, with healthcare and financial institutions facing heightened regulatory demands under the Abu Dhabi Healthcare Information and Cyber Security Standards (ADHICS). Recent high-profile data breaches and cyber threats have highlighted the urgent need for organizations to comply fully with these standards, protecting sensitive patient and financial information. As organizations scramble to adapt, MIT Consultants, a Dubai-based cybersecurity advisory and solutions reseller, is becoming a pivotal player in assisting healthcare and financial institutions in navigating the complexities of ADHICS compliance. Expert Advisors, Tailored Solutions MIT Consultants differentiates itself through its vendor-neutral advisory approach, ensuring that the solutions recommended are best suited to each organization's specific operational and compliance needs. Rather than advocating for a particular product, the firm's cybersecurity experts thoroughly analyze an institution's existing infrastructure, identify vulnerabilities, and align their recommendations precisely with ADHICS requirements. "Our role goes beyond mere reselling of cybersecurity solutions," says Mohamed Moussous, CEO of MIT Consultants. "We see ourselves as strategic partners. Our clients benefit from our ability to pinpoint precisely what's needed to achieve compliance efficiently and securely." Addressing Critical Cybersecurity Needs Healthcare and financial institutions face particular vulnerabilities—ransomware, phishing attacks, insider threats—all of which ADHICS compliance seeks to mitigate through rigorous cybersecurity measures. MIT Consultants addresses these threats by implementing robust Privileged Access Management (PAM), real-time threat detection systems, patch management processes, and secure information management strategies tailored specifically to ADHICS regulations. Real-World Successes MIT Consultants has successfully guided numerous institutions through ADHICS compliance by identifying gaps, providing detailed roadmaps, and recommending integrated solutions from global cybersecurity vendors. Their expertise ensures minimal operational disruption while achieving full regulatory adherence, ultimately safeguarding institutions from both cyber threats and potential regulatory penalties. "With our deep understanding of the UAE cybersecurity landscape, we provide not just technical solutions but peace of mind," adds Moussous. "Our clients trust us because we have their best interests at heart, which is compliance, security, and operational efficiency." A Strategic Advantage In an environment where regulatory compliance and cybersecurity intersect critically, MIT Consultants offers UAE healthcare and financial institutions a significant strategic advantage. By entrusting compliance initiatives to specialized cybersecurity advisors, organizations can stay ahead of threats, ensure adherence to regulations, and maintain a secure operational environment. As ADHICS continues to shape the future of cybersecurity compliance in the UAE, MIT Consultants stands out as an indispensable ally, turning complex regulatory challenges into clear, actionable strategies. Mohamed Moussous, CEO of MIT ConsultantsIRIS BAY - Business Bay Dubai Website: of the Group : CONTACT: mmoussous@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Mars and Pairwise Collaborate to Accelerate Cacao Research and Development
Durham, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mars, Incorporated has licensed Pairwise's Fulcrum® gene editing tools for cacao research and development. This licensing agreement grants Mars access to Pairwise's CRISPR tools, including the SHARC™ enzyme. The Pairwise Fulcrum platform encompasses gene editing tools, enzymes and trait libraries, enabling precise changes that unlock the plant's inherent potential. This capability significantly accelerates the development of impactful crop traits compared to traditional breeding methods, allowing for the activation or deactivation of characteristics and fine-tuning traits, much like adjusting a dimmer switch to achieve optimal results. Mars aims to develop this advanced plant breeding technology to improve cacao production and effectively tackle agricultural challenges. The ultimate goal is to help address the pressures cacao faces globally from climate variability, plant diseases and environmental stresses. This strategic initiative underscores the potential of this technology to drive meaningful advancements in agriculture. "At Mars, we believe CRISPR has the potential to improve crops in ways that support and strengthen global supply chains," said Carl Jones, Plant Sciences Director at Mars. "Our focus is to transparently and responsibly conduct CRISPR research in plant science that helps crops better adapt to climate challenges, disease pressures and resource constraints." "We're pleased to provide Mars with access to our Fulcrum platform for their cacao research and development initiatives," said Ian Miller, Chief Operating Officer at Pairwise. "Plant breeding innovation has the potential to help address important agricultural challenges, and we look forward to supporting Mars' research goals." The Pairwise Fulcrum platform includes gene editing tools, enzymes and trait libraries, enabling precise changes that unlock the plant's inherent potential to greatly accelerate the development of impactful crop traits compared to traditional breeding methods.### About Pairwise Pairwise is agriculture's gene editing powerhouse, building a healthier world through partnership and plant innovation. Co-founded by the inventors of CRISPR, our Fulcrum® Platform accelerates the development of climate-resilient, nutritious, and sustainable crops. As trusted partners to global industry leaders and nonprofit institutions, we help breeders move faster while transforming food and agriculture for farmers, consumers, and the planet. Founded in 2017 and based in Durham, NC, Pairwise is committed to delivering innovation that makes food easier to grow and better to eat. For more information, visit CONTACT: Communications Pairwise communications@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
